AMENDMENTS TO THE CLAIMS IN RESPONSE TO FINAL OFFICE ACTION

1. **(Currently Amended)** A compound according to formula I



(I)

wherein

P is phenyl;

R^1 is attached to P via a carbon atom on ring P and is selected from the group consisting of hydrogen, halo, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkylOR^5, C_{0-6}alkylcyano and C_{0-6}alkylNR^5R^6;

X^1 is selected from the group consisting of N, NR^4 and CR^4;

X^2 is selected from the group consisting of C and N;

X^3 is selected from the group consisting of N and O;

X^4 is selected from the group consisting of CR^4, N, NR^4 and O;

X^5 is ~~**selected from the group consisting of**~~ a bond~~**, $CR^4R^{4'}$, NR^4, O, S, SO and SO_2**~~;

X^6 is N;

X^7 is selected from the group consisting of C and N;

R^4 ~~**and $R^{4'}$ are independently**~~ **is** selected from the group consisting of hydrogen, halo, C_{1-6}alkyl and C_{1-6}alkylhalo;

Q is triazolyl;

each R^3 are independently selected from the group consisting of: hydroxy, oxo, C_{1-4}alkylhalo, halo, C_{1-6}alkyl and $(CO)OC_{1-4}$alkyl;

each R^2 [[and R^3]] are independently selected from the group consisting of**:** hydroxy, ~~C_{0-6}alkylcyano,~~ oxo, ~~$=NR^5$, $=NOR^5$,~~ C_{1-4}alkylhalo, halo, C_{1-6}alkyl, C_{3-6}cycloalkyl, **aryl,** $C_{[[0]]1-6}$alkylaryl, **heteroaryl,** $C_{[[0]]1-6}$alkylheteroaryl, C_{1-6}alkylcycloalkyl, **heterocycloalkyl,** $C_{[[0]]1-6}$alkylheterocycloalkyl, OC_{1-4}alkyl, ~~OC_{0-6}alkylaryl, $O(CO)C_{1-4}$alkyl, $(CO)OC_{1-4}$alkyl,~~ **$(S)C_{1-4}$alkyl,** $C_{[[0]]1-4}$alkyl$(S)C_{[[0]]1-4}$alkyl, ~~C_{1-4}alkyl$(SO)C_{0-4}$alkyl, C_{1-4}alkyl$(SO_2)C_{0-4}$alkyl, $(SO)C_{0-4}$alkyl, $(SO_2)C_{0-4}$alkyl, C_{1-4}alkylOR^5, C_{0-4}alkylNR^5R^6~~ and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N and O and wherein said ring and said fused ring may be substituted by one or more A;

wherein any C_{1-6}alkyl, aryl, or heteroaryl defined under R^1, R^2 and R^3 may be substituted by one or more A;

A is selected from the group consisting of: hydrogen, hydroxy, halo, ~~nitro,~~ oxo, **cyano,** $C_{[[0]]1-6}$alkylcyano, **C_{3-6}cycloalkyl,** $C_{[[0]]1-4}$alky1C_{3-6}cycloalkyl, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkylhalo, OC_{1-6}alkylhalo, C_{2-6}alkenyl, **aryl,** $C_{[[0]]1-3}$alkylaryl, **OR^5,** $C_{[[0]]1-6}$alkylOR^5, ~~OC_{2-6}alkylOR^5;~~ **SR^5,** $C_{[[0]]1-6}$alkylSR^5, ~~OC_{2-6}alkylSR^5;~~ $(CO)R^5$, $O(CO)R^5$, ~~OC_{2-6}alkylcyano, OC_{1-6}alkylCO_2R^5, $O(CO)OR^5$, OC_{1-6}alkyl$(CO)R^5$, C_{1-6}alkyl$(CO)R^5$;~~ NR^5OR^6, **NR^5R^6,** $C_{[[0]]1-6}NR^5R^6$, ~~OC_{2-6}alky1NR^5R^6, C_{0-6}alkyl$(CO)NR^5R^6$, OC_{1-6}alkyl$(CO)NR^5R^6$, OC_{2-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)R^6$, C_{0-6}alkyl$NR^5(CO)NR^5R^6$, $O(CO)NR^5R^6$, C_{0-6}alkyl$(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)NR^5R^6$, C_{0-6}alkyl$NR^5(SO_2)R^6$, OC_{2-6}alkyl$NR^5(SO_2)R^6$, SO_3R^5, C_{1-6}alkyl$NR^5(SO_2)NR^5R^6$, OC_{2-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO_2)R^5$, C_{0-6}alkyl$(SO)R^5$, OC_{2-6}alkyl$(SO)R^5$~~ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from, H, C_{1-6}alkyl, C_{3-7}cycloalkyl and aryl;

m is 1 or 2;

n is selected from 0, 1, 2, 3 or 4;

p is selected from 0, 1, 2, 3 or 4; or

a pharmaceutically acceptable salt thereof.

2. **(Canceled)**.

3. **(Original)** A compound according to claim 1 wherein X^7 is C.

4. **(Canceled)**.

5-9. **(Canceled)**.

10. **(Previously Presented)** A compound according to claim 1 wherein R^1 is selected from the group consisting of: Cl, F, Me, OMe, CF_3, OCF_3, and CN.

11. **(Original)** A compound according to claim 1 wherein X^2 is C.

12. **(Original)** A compound according to claim 11 wherein X^1 is N or CR^4.

13. **(Original)** A compound according to claim 12 wherein when X^3 is O, X^4 is N and when X^3 is N, X^4 is O.

14. **(Original)** A compound according to claim 1 wherein X^2 is N.

15. **(Original)** A compound according to claim 14 wherein X^1 is N.

16. **(Original)** A compound according to claim 15 wherein X^3 is N and X^4 is N or CR^4.

17. **(Canceled)**.

18. **(Currently Amended)** A compound according to claim 12 wherein X^5 is ~~**selected from the group consisting of**~~ a bond~~**, $CR^4R^{4'}$, NR^4 and O**~~.

19. **(Currently Amended)** A compound according to claim 13 wherein X^5 is ~~selected from the group consisting of~~ a bond~~, O and NR^4~~.

20. **(Canceled)**.

21-24. **(Canceled)**.

25. **(Currently Amended)** A compound according to claim 1 wherein **each** R^2 **[[and R^3]]** are independently selected from the group consisting of**:** C_{1-4}alkylhalo, C_{1-6}alkyl, C_{3-6}cycloalkyl, **aryl,** $C_{[[0]]1-6}$alkylaryl**, heteroaryl,** and $C_{[[0]]1-6}$alkylheteroaryl**; and**

each R^3 are independently selected from the group consisting of: C_{1-4}alkylhalo and C_{1-6}alkyl.

26. **(Currently Amended)** A compound according to claim 1 wherein A is selected from the group consisting of hydrogen, hydroxyl, halo, **cyano,** $C_{[[0]]1-6}$alkylcyano, C_{1-6}alkyl, OC_{1-6}alkyl, C_{1-6}alkylhalo, **and** OC_{1-6}alkylhalo.

27. **(Currently Amended)** A compound ~~according to claim 1~~ selected from **the group consisting of**

~~4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)--pyridine,~~

~~3-[5-(3-Chloro-phenyl)-isoxazol-3-y1]-4-(4-methy1-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,~~

~~3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine,~~

~~3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,~~

~~3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine,~~

~~3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester,~~

~~2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-1,2,4]triazol-3-yl)-piperazine,~~

~~2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine,~~

~~3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester,~~

~~2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine,~~

~~2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-4-methyl-piperazine,~~

~~2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4- triazol-3-yl}piperidine~~

~~4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3- yl)pyridine,~~

~~2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]piperidine,~~

~~[4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3- yl)phenyl]dimethylamine,~~

~~[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-benzyl-dimethyl-amine,~~

~~{2-[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-phenoxy]-ethyl}-dimethyl-amine,~~

~~(R)-3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,~~

~~(S) 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine,~~

~~(R)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methy1-4H-1,2,4-triazol-3-yl}piperidine,~~

~~(S)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H1,2,4-triazol-3-yl}piperidine,~~

~~(R)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine,~~

~~(S)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine~~

4-[5-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-y1}-4-cyclopropyl-4H-[1,2,4]triazol-3-yl)-pyridin-2-yl}-morpholine,

4-[5-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridin-2-yl}-morpholine,

3-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine,

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-4-cyclopropyl-4H-[1,2,4]triazol-3-

yl)-pyridine,

~~3-[5-(3-Chloro-phenyl)-[1,2,4]oxadioazol-3-yl]-4-(5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)- morpholine,~~

~~3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4-cyclopropyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)morpholine,~~

~~3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4-cyclopropyl-5-pyridin-4-yl-4H-1,2,4-triazol-3- yl)morpholine,~~

~~3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-(4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3- yl)morpholine,~~

~~3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(6-methoxy-pyridin-3-yl)-4-methyl-4H[1,2,4]triazol-3-yl-morpholine,~~

~~3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(2-methoxypyridin-4-yl)-4-methyl-4H-1,2,4- triazol-3-yl]morpholine,~~

~~3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(2-methylpyridin-4-yl)-4-methyl-4H-1,2,4- triazol-3-yl]morpholine,~~

~~3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(5-fluoropyridin-3-yl)-4-methyl-4H-1,2,4- triazol-3-yl]morpholine,~~

~~3-[5-(3-chlorophenyl)isoxazol-3-y1]-4-[5-(5-fluoropyridin-3-yl)-4-methyl-4H-1,2,4-triazol-3- yl]morpholine,~~

~~3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-2-yl-4H-1,2,4-triazol-3- yl)morpholine,~~

~~4-[5-(5-fluoropyridin-3-yl)-4-methy1-4H-1,2,4-triazol-3-yl]-3-[3-(3-iodophenyl)-1,2,4-~~

~~oxadiazol5-yl]morpholine,~~

~~3-[3-(3-iodophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-1,2,4-triazol-3- yl)morpholine,~~

~~3-[5-(3-chlorophenyl)isoxazol-3-yl]-4-[5-(2-methylpyridin-4-yl)-4-methyl-4H-1,2,4-triazol-3- yl)morpholine,~~

~~3-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-4-(4-methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)morpholine,~~

~~3-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]-4-[5-(3,5-difluorophenyl)-4-methyl-4H-1,2,4-triazol-3-yl]morpholine,~~

3-(5-{2-[5-(3-chlorophenyl)isoxazol-3-yl]pyrrolidin-l-yl}-4-cyclopropyl-4H-1,2,4-triazol-3-yl)pyridine, and

4-(5-{2-[5-(3-chlorophenyl)isoxazol-3-yl]pyrrolidin-l-yl)-4-methyl-4H-1,2,4-triazol-3-yl)pyridine.

28. **(Canceled)**.

29. **(Canceled)**.

30. **(Canceled)**.

31. **(Canceled)**.

32. **(Canceled)**.

33. (**Previously Presented – Withdrawn**) A method of treatment of mGluR 5 mediate disorders, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to claim 1.

34. **(Previously Presented – Withdrawn)** The method according to claim 33, wherein the disorders mediated by mGluR 5 are neurological disorders.

35. **(Previously Presented – Withdrawn)** The method according to claim 33, wherein the disorders mediated by mGluR 5 are psychiatric disorders.

36. **(Previously Presented – Withdrawn)** The method according to claim 33, wherein the disorders mediated by mGluR 5 are chronic and acute pain disorders.

37. **(Previously Presented – Withdrawn)** The method according to claim 33, wherein the disorders mediated by mGluR 5 are gastrointestinal disorders.

38. **(Withdrawn)** A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell containing said receptor with an effective amount of the compound according to claim 1.